The company shared findings from an abstract examining outcomes in a nonprofit, community-based medical center using an advanced practice provider (APP)-driven protocol for WCD therapy. Kestra says it represents one of the first analyses of its kind.
Investigators presented findings at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego.
The Kirkland, Washington-based company designed Assure to provide autonomous detection and defibrillation for ventricular arrhythmias. It can also detect and record other clinically significant arrhythmias. The modern wearable defibrillator system received FDA approval in 2021.
Kestra said the analysis revealed high patient compliance for the WCD. That includes a median daily wear time of 23.3 hours and consistent usage. That usage often extended beyond 90 days, highlighting the importance of sustained device use in protecting patients at risk of sudden cardiac death.
According to a news release, investigators detected arrhythmias in 4% of patients, even with a predominantly primary prevention population. This underscores the importance of real-time monitoring and early intervention, Kestra said. With those who received therapy, the outcomes reflect effective continuity of care. Patients benefitted from timely escalation through implantable cardioverter defibrillator (ICD) placement or hospitalization.
The study also highlighted how an APP-driven care model successfully delivered WCD therapy in alignment with guideline-based recommendations. Kestra said it ensured that all indicated patients received appropriate care.
This data publication marks another recent milestone for Kestra, which last month went public following an upsized initial public offering (IPO).
Additionally, last summer, the company brought in $196 million in an oversubscribed financing round. Weeks later, it added medtech veteran and longtime Axonics CEO Raymond Cohen to its board as well.
